Lipidica

We are delighted to announce that Lipidica Laboratory has successfully been reaccredited by the Czech Accreditation Institute (Český institut pro akreditaci, o.p.s.) in accordance with the ČSN EN ISO 15189 ed. 3:2023 standard. We have met all the requirements for the quality and competence of a medical laboratory.

This milestone is essential for us to continue with our clinical study, bringing us closer to our goal of enabling the early detection of pancreatic cancer in clinical practice with potential to save many lives each year.

Method for detecting pancreatic cancer

We are happy to share with you great news – our innovative method for early detection of pancreatic cancer was successfully patented in the United States of America in March! This significant milestone is the result of an almost five-year process, during which it underwent a thorough assessment by the US patent offices.

The patent applies to our diagnostic method, which enables the detection of pancreatic cancer using the analysis of lipids from blood. A detailed description of the method on 75 pages confirms its scientific and clinical value.

Obtaining a US patent significantly advances the potential of using screening tests and complements patents granted in the EU, Japan and Singapore.